GLP-1 medications influence appetite and glucose regulation, but they do not independently preserve muscle mass
Clinical trial context: plateau does not mean failure Clinical trial data helps put this into perspective
If you require specific protein targets, a registered dietitian can provide personalised advice based on your individual needs and circumstances
If symptoms are particularly troublesome, your doctor may recommend: Slower dose escalation than standard protocols Temporary dose reduction Switching to a different GLP-1 agonist, as individual responses vary Short-term use of anti-diarrhoeal medications such as loperamide for acute episodes, though this should only be done under medical supervision and avoided if you have blood in your stool, fever, or suspected infection If you're also taking insulin or sulfonylureas, monitor your blood glucose more frequently during periods of reduced appetite or diarrhoea, as you may need dose adjustments to prevent hypoglycaemia
So far, preclinical and observational data examining the effects of GLP1Ra-based therapies on bone suggest a positive association, whereby GLP1Ra use reduces turnover and promotes bone formation ( 2 (95% CI: 0.01 to 0.04)
